company background image
CJH logo

CanSino Biologics BST:CJH Stock Report

Last Price

€3.78

Market Cap

€1.6b

7D

20.4%

1Y

n/a

Updated

07 Dec, 2024

Data

Company Financials +

CJH Stock Overview

Develops, manufactures, and commercializes vaccines in the People’s Republic of China. More details

CJH fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

CanSino Biologics Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for CanSino Biologics
Historical stock prices
Current Share PriceHK$3.78
52 Week HighHK$3.84
52 Week LowHK$1.85
Beta0.46
11 Month Change20.38%
3 Month Changen/a
1 Year Changen/a
33 Year Change-76.19%
5 Year Change-31.27%
Change since IPO-20.44%

Recent News & Updates

Recent updates

Shareholder Returns

CJHDE BiotechsDE Market
7D20.4%1.5%3.2%
1Yn/a-14.5%9.7%

Return vs Industry: Insufficient data to determine how CJH performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how CJH performed against the German Market.

Price Volatility

Is CJH's price volatile compared to industry and market?
CJH volatility
CJH Average Weekly Movementn/a
Biotechs Industry Average Movement6.8%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.5%
10% least volatile stocks in DE Market2.4%

Stable Share Price: CJH's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine CJH's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
20091,149Xuefeng Yuwww.cansinotech.com

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination.

CanSino Biologics Inc. Fundamentals Summary

How do CanSino Biologics's earnings and revenue compare to its market cap?
CJH fundamental statistics
Market cap€1.58b
Earnings (TTM)-€93.78m
Revenue (TTM)€97.48m

10.2x

P/S Ratio

-10.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CJH income statement (TTM)
RevenueCN¥748.53m
Cost of RevenueCN¥774.40m
Gross Profit-CN¥25.87m
Other ExpensesCN¥694.25m
Earnings-CN¥720.11m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.91
Gross Margin-3.46%
Net Profit Margin-96.20%
Debt/Equity Ratio41.3%

How did CJH perform over the long term?

See historical performance and comparison